Pao-Chen has diverse experience from drug discovery as a bench scientist to drug development as a regolaoty project manger and clinical scientist. As a clinical scientist at Nektar Therapeutics, Pao-Chen works closely with the medical monitor and cross-functional team on bladder cancer studies for study protocol design, communication with health authorities and investigators, sites initiation and data review. Prior to Nektar, Pao-Chen worked as a regulatory project manager managing the timelines for milestones submissions at Gilead for 9 marketed products and 5 developing products in HIV, inflammation and liver diseases therapeutic areas. Prior to Gilead, she was a drug discovery research scientist program lead at Assembly Biosciences, a small biotech company developing treatments for Hepatitis B virus infected patients. She led cell assay development, high-throughput screening, CRO management, and participated in IND enabling studies. Pao-Chen received her PhD in Molecular Biology at University of Southern California and did her postdoctoral training at Gladstone Institutes, UCSF.